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Abstract We describe functional binding sites for the tumor
suppressor p53 and for NFUB residing in the promoter of the
novel human early response gene p22/PRG1 (IEX-1/DIF-2). Gel
shift and supershift assays demonstrate binding of p53 and NFUB
to their corresponding sites in vitro. CAT-reporter gene assays
show transactivation of the human p22/PRG1 promoter by p53 in
Hep3B cells stably transfected with a temperature-sensitive
mutant p53, but not in p53-deficient Hep3B cells. TNFK induced
NFUB dependent transactivation was shown in HepG2 cells or in
818-4 pancreatic cancer cells. These data imply that human p22/
PRG1 is a target gene for p53 and NFUB involved in growth
regulation and stress response.
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1. Introduction
The novel proliferation associated early response gene p22/
PACAP response gene1 (PRG1) is expressed in rats [1], mice
(gly96) [2] and humans (IEX1/DIF2) [3,4]. Besides its early
transcriptional induction during growth stimulation in various
cell types [1,2], the induction of this gene has also been dem-
onstrated in irradiated human breast cancer cells [3] or in
human monocytes before their di¡erentiation into macro-
phages [4]. In humans, p22/PRG1 represents a 22-kDa protein
comprising 156 amino acids, yet the exact function and cel-
lular localization is unclear. Current data strongly indicate
that p22/PRG1 may be involved in distinct cellular processes
like stimulation of proliferation, cellular adaptation and stress
response. More recently, we could show that rat p22/PRG1 is
a target gene for the tumor suppressor p53 presumably in-
volved in p53-dependent growth regulation [5]. However, the
detailed role of p22/PRG1 in this context is still under inves-
tigation. Meanwhile, we and others [6] have also cloned parts
of the human p22/PRG1 promoter providing the opportunity
to elucidate the signal transduction mechanisms leading to
transactivation of p22/PRG1 in humans. In this study, we
demonstrate that, as in rats, the human p22/PRG1 promoter
contains also functional binding sites for p53 and for NFUB,
both responsible for the induction of p22/PRG1 during regu-
lation of cellular growth, stress response and cellular adap-
tion.
2. Material and methods
2.1. Materials
Recombinant wild-type and mutant p53 and pCMV-p53 and
pCMV-C5 expression vectors were a generous gift from Prof.
W. Deppert, Heinrich Pette Institute, Hamburg, Germany.
Hep3B(p53Val135) and Hep3B cells were kindly provided by Prof. P.
Galle, 1st Dept. of Medicine, University of Mainz, Germany. Oligo-
nucleotides were custom synthesized by Biometra (Goºttingen, Ger-
many), [Q-32P]dATP was from Amersham (Braunschweig, Germany)
and cell culture media were from Seromed (Hamburg, Germany).
2.2. Cell culture
Hep3B(p53Val135) and Hep3B cells were grown in EMEM (0.1 mg/
ml Na-pyruvate; 1% glutamine; 10% FCS) þ 500 Wg/ml G418 (Clon-
tech). HepG2 cells were cultured in DMEM (high glucose, 1% gluta-
mine, 10% FCS) and 818-4 pancreatic carcinoma cells and HeLa cells
were cultured in RPMI (1% glutamine; 10% FCS).
2.3. Gel shift and supershift assays
For p53 gel shifts, puri¢ed recombinant baculovirus expressed wt
p53 or double mutated p53-C5 (80 ng) were incubated in incubation
bu¡er (Stratagene) together with a Q-32P-labelled oligonucleotide
(aggtgccacatgctccgacatgtgcctgca) containing the p53 binding site
from the human p22/PRG1 promotor. For NFUB gel shifts, nuclear
extracts from TNFK-stimulated Jurkat cells were prepared as de-
scribed recently [7] and incubated with a Q-32P-labelled oligonucleotide
(aatcgtcggaatttccagcccg) containing the NFUB binding site from the
human p22/PRG1 promoter or a consensus NFUB-binding site. After
30 min incubation at room temperature, samples were submitted to
native PAGE. Gels were dried and exposed to X-ray Hyper¢lm
(Amersham). For supershift assay, a monoclonal p53 antibody
(Ab1, Calbiochem) or anti p65/p50 NFUB antibodies (Santa Cruz)
were added for 1 h, 4‡C.
2.4. Generation of CAT-reporter gene constructs
Using appropriate composite HindIII/XbaI and SalI/XbaI PCR-
primers, PCR-fragments of the human p22/PRG1 promoter were gen-
erated containing deletions in positions 3226/3244 and 3106/3111
(vp53, v3NFUB) or shortened at the 5P-end (pos. +1 to 3439, 3335,
3285, 3225, 3140, and 3110). Products were cloned into the CAT-
basic vector (Promega) and checked by nucleotide sequencing.
2.5. Cell transfection and CAT-reporter gene assay
Hep3B(p53Val135), Hep3B, HepG2 and 818-4 cells cultured in 6-well
plates were transiently transfected (Lipofectamine; Gibco-BRL) with
pCAT vectors (1.5 Wg) containing human p22/PRG1 promoter frag-
ments and 0.5 Wg pCMV-lacZ. For cotransfection of Hep3B cells, 0.1
Wg of CMV early enhancer promoter driven expression plasmids for
wild-type p53 (pCMV-p53) or mutant p53 (pCMV-c5p53) were added.
After 24 h culture, CAT expression (ng) was determined by ELISA
(Boehringer) and normalized to L-galactosidase expression (L-gal
ELISA, Boehringer).
3. Results
By means of promoter ¢nder PCR, we cloned a 1864-bp
genomic fragment of human p22/PRG1 identical to a recently
published genomic sequence of the human DIF-2 gene [6].
This fragment consists of a 112-bp intron and a 633-bp
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5P-£anking sequence harboring the putative p22/PRG1 pro-
moter (Fig. 1). Several potential binding sites were identi¢ed
including an NFUB binding site (pos. 3113 to 3104) that is
conserved between promoters of human and rat p22/PRG1 [1]
or murine gly96 [2]. A potential p53 binding site is located in
the human gene (pos. 3226 to 3245) at a quite similar posi-
tion and with almost complete sequence identity compared to
the functional p53 binding site of the rat p22/PRG1 promoter
[5]. This site, ccACATGCCT cGACATGTgC, strongly
matches the tandem consensus sequence (RRRCWWGYYY)2
[8,9] common to established p53 target genes like p21/Waf1,
Bax, mdm2 or GADD45 [10^13].
To elucidate whether these two conserved and prominent
binding sites bind to NFUB and p53 in vitro, gel shift assays
were performed. For gel shift assays on NFUB, nuclear ex-
tracts from TNFK-stimulated Jurkat cells were used. As
shown in Fig. 2A, an intensively labelled protein/DNA com-
plex could be detected when coincubating the nuclear extract
and the NFUB probe derived from the p22/PRG1 promoter.
The addition of an excess of the homologous unlabelled oligo
completely reduced labelling of the protein/DNA complex,
whereas an unrelated oligo ^ like AP1 ^ did not compete
with the probe. The speci¢city of the identi¢ed protein/DNA
complex was underlined by the appearance of a supershifted
ternary complex with monoclonal antibodies against p65 and
p50 (Fig. 2A).
Using a radiolabelled oligo containing the p53 binding site
from the human p22/PRG1 promoter as probe, coincubation
with recombinant wt-p53 similarly produced an intensive ra-
diolabelled protein/DNA complex (Fig. 2B). Labelling of this
complex was fully abolished by the addition of an excess of
the homologous unlabelled oligonucleotide and no band was
observed when incubating the p53 probe with recombinant
double mutant p53 [14]. Furthermore, the addition of an
anti wt-p53 monoclonal antibody led to the formation of a
supershifted ternary complex.
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Fig. 1. Partial nucleotide sequence of the human p22/PRG1 pro-
moter (pos. 3633 to 31). Sequence of the 633-bp 5P-£anking region
of the human p22/PRG1 gene harboring the putative promoter.
Binding sites for transcription factors are double-underlined and in-
dicated above. This sequence has been deposited in the EMBL data
base, accession no. X96438.
Fig. 2. Gel shift and supershift assay. A: Using nuclear extracts
from TNFK-stimulated Jurkat cells, gel shift assays were performed
with equal amounts of the Q-32P-labelled oligonucleotide containing
the NFUB binding site of the human p22/PRG1 promoter. B: Using
baculovirus recombinant wild-type p53 (lanes 1, 3, 4) or recombi-
nant mutant p53-C5 (lane 2), gel shift assays were performed with
equal amounts of the Q-32P-labelled oligonucleotide containing p53
binding site of the human p22/PRG1 promoter. Assays were con-
ducted in the absence or presence of a 50-fold molar excess of unla-
beled oligo, or in the presence of monoclonal antibody against p65/
p50 (A) or the C-terminal domain of wild-type p53 (B).
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To test the potential of the NFUB and p53 binding sites to
drive transactivation of the human p22/PRG1 promoter, CAT
reporter gene assays with various modi¢ed promoter frag-
ments of human p22/PRG1 were performed. As shown in
Fig. 3A and B, fragments of the human p22/PRG1 promoter
containing the NFUB binding site mediate strong transcrip-
tional induction (s 300%) of the CAT gene in transiently
transfected HepG2 or 818-4 cells in response to TNFK. This
TNFK-dependent increase of CAT expression was not ob-
served in cells transfected with those CAT-reporter gene con-
structs lacking the NFUB binding site. Instead, in these trans-
fectants CAT expression was slightly decreased (up to 20%)
by TNFK.
A temperature-dependent increase of CAT expression was
observed in Hep3B cells stably transfected with the
(Val135)p53, an inactive temperature-sensitive mutant p53.
At the permissive temperature of 32‡C promoting formation
of a wild-type like con¢guration of (Val135)p53, CAT expres-
sion was elevated (3^4-fold) in cells transfected with p22/
PRG1-promoter constructs containing the p53-binding site
(Fig. 4A), but not in cells transfected with constructs lacking
this site by either deletion or by 5P-truncation. In contrast, no
temperature-dependent and site-restricted increase of CAT ex-
pression occurred in p53-de¢cient Hep3B cells. In these cells,
CAT levels decreased at the permissive temperature. Transient
cotransfection of Hep3B cells with CAT promoter constructs
and a CMV promoter driven expression vector for wild-type
p53 [15] led to a p53-dependent increase of CAT expression
(6^10-fold) only in cells receiving promoter constructs con-
taining the p53 binding site, but not in transfectants lacking
this site (Fig. 4B). In contrast, cotransfection with an expres-
sion plasmid for mutant p53 (pCMV-c5p53) resulted in no
site-restricted increase of CAT expression.
4. Discussion
Similar to the rat p22/PRG1 gene, the promoter of human
p22/PRG1 contains highly conserved binding sites for NFUB
and p53 at almost identical positions. This high degree of
conservation that can be extended to the murine homologue
gly96 [2] indicates an essential role of these promoter ele-
ments. As expected from the high identity with the corre-
sponding consensus sequences [8,9,16], we could demonstrate
that NFUB and p53 both speci¢cally interact with the human
p22/PRG1 promoter in vitro and in vivo. In accordance with
our recent ¢nding that p22/PRG1 expression is induced by
TNFK in pancreatic carcinoma cells (Schaºfer H. et al., manu-
script in preparation), recruitment of NFUB by TNFK in
HepG2 and 818-4 cells was followed by activation of the
human p22/PRG1 promoter. This activation clearly depends
on the presence of the NFUB binding site since no induction
of CAT expression in response to TNFK was observed when
this site was deleted from the p22/PRG1 promoter. Therefore,
it can be assumed that p22/PRG1 is involved in biological
actions of TNFK mediated via NFUB. These actions include
anti-apoptotic survival functions that initiate at the TNFR-1
receptor and its interaction with TRAF-2 [17]. Similar to the
stress response (UV-light, Q-irradiation) [3] that also involves
NFUB activation, recruitment of p22/PRG1 by TNFK may
contribute to a cellular survival and regeneration program.
Another even more meaningful ¢nding of this study is the
presence of a functional binding site for the tumor suppressor
p53 in the promoter of human p22/PRG1. By demonstrating
binding of wild-type p53 to the p53 binding site in vitro as
well as p53-dependent transactivation via this site, we provide
now ¢rst evidence that p22/PRG1 may be a target gene for
p53, as already shown for rat p22/PRG1 [5]. In its predom-
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Fig. 3. E¡ect of TNFK on transcriptional activity of the p22/PRG1
promoter. HepG2 (A) and 818-4 (B) cells were transiently co-trans-
fected with CAT reporter-gene vectors containing the depicted frag-
ments of the human p22/PRG1 promoter and pCMVlacZ, as trans-
fection control. Upon subsequent stimulation with 0.2 nM TNFK
for 6^8 h, CAT expression was quanti¢ed by a CAT-ELISA and
normalized to L-galactosidase activity. Basal activity was determined
in cells treated with PBS (mean þ S.D., n = 4).
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inant function as transcription factor [18], p53 recruits genes
that are involved in growth arrest and DNA-repair or in
apoptosis [19]. The actions of these genes interrupt division
of DNA damaged cells or even eliminate them by initiation of
the cellular suicide program. This is to prevent propagation of
potentially mutated cells and the lack of such a p53-dependent
growth control is a major cause of cancer. The recruitment of
p22/PRG1 by p53 may be related to another mode of p53-
dependent growth regulation [20,21] in that cells recovered
from DNA damage are allowed to reenter the cell cycle and
thus to survive.
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